Advertisement

Dissemination (Meeting Coverage)

Survival Trends of NSCLC Diagnosed in 2012 vs 2019

Significant improvements in mortality among non-small cell lung cancer (NSCLC) cancer patients have been reported over the past 2 decades, according to Surveillance, Epidemiology, and End Results Program (SEER) data. The timing...

Read More

ctDNA Predicts Early Relapse in NSCLC

Liquid biopsies based on circulating tumor DNA (ctDNA) analysis are being investigated for detection of residual disease and recurrence in patients with early-stage non-small cell lung cancer (NSCLC). Due to low ctDNA levels in...

Read More

Exercise And Quality Diet After Leukemia

A 24-month phone and app/web-based diet and physical activity intervention that was successful for weight loss in the general population did not result in greater weight loss or improvement in cardiovascular (CV) risk factors...

Read More

Palliative Care And Coping In Patients With AML

Palliative care and coping in patients with acute myeloid leukemia receiving intensive induction therapy: A mediation analysis of data from a randomized trial.   Integrated palliative and oncology care (IPC) as part of...

Read More

IO-Only or in Chemo-IO Regimens NSCLC Subgroups

Immunotherapy (IO) + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic non-small cell lung cancer (NSCLC), with IO-only therapy approved only for PD-L1+ NSCLC. Patients with PD-L1 scores from...

Read More

For latest news and updates
Email-id is invalid